Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins

Anja Moldenhauer, Richard C. Frank, Javier Pinilla-Ibarz, Gudrun Holland, Piernicola Boccuni, David A. Scheinberg, Abdulgabar Salama, Karl Seeger, Malcolm A S Moore, Stephen D Nimer

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells (DC) to induce a leukemia-specific immune response. In this study, three leukemic cell lines were investigated: Kasumi-1 and SKNO-1 (two acute myeloid leukemia (AML) cell lines carrying the (8;21)-chromosomal translocation, resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one) and REH, an acute lymphoblastic leukemia cell line with the (12;21)-chromosomal translocation and expression of translocation ETS-Bke leukemia-AML1. These fusion proteins are implicated in the pathogenesis of the lenkende state by recruiting corepressors and histone deacetylases (HDAC), which interfere with normal cell differentiation. In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor α, granulocyte macrophage-colony stimulating factor, c-kit ligand, and soluble CD40 ligand; yet, addition of the HDAC inhibitor (Hdi) trichostatin A enhanced DC differentiation with retention of the fusion transcripts. These leukemic DC showed high-level CD83 and human leukocyte antigen (HLA)-DR expression and had a high allostimulatory potential. Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42% in parental Kasumi-1 and 83% in parental REH cells, respectively. This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins.

Original languageEnglish
Pages (from-to)623-633
Number of pages11
JournalJournal of Leukocyte Biology
Volume76
Issue number3
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Fingerprint

Histone Deacetylases
Dendritic Cells
Cell Differentiation
Cell Line
Genetic Translocation
Leukemia
Proteins
Histone Deacetylase Inhibitors
HLA Antigens
trichostatin A
T-Lymphocytes
Co-Repressor Proteins
CD40 Ligand
Stem Cell Factor
Myeloid Cells
Granulocyte-Macrophage Colony-Stimulating Factor
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Chromosome Aberrations
Tumor Necrosis Factor-alpha

Keywords

  • Leukemia
  • Translocation
  • Vaccination

ASJC Scopus subject areas

  • Cell Biology

Cite this

Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. / Moldenhauer, Anja; Frank, Richard C.; Pinilla-Ibarz, Javier; Holland, Gudrun; Boccuni, Piernicola; Scheinberg, David A.; Salama, Abdulgabar; Seeger, Karl; Moore, Malcolm A S; Nimer, Stephen D.

In: Journal of Leukocyte Biology, Vol. 76, No. 3, 01.09.2004, p. 623-633.

Research output: Contribution to journalArticle

Moldenhauer, A, Frank, RC, Pinilla-Ibarz, J, Holland, G, Boccuni, P, Scheinberg, DA, Salama, A, Seeger, K, Moore, MAS & Nimer, SD 2004, 'Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins', Journal of Leukocyte Biology, vol. 76, no. 3, pp. 623-633. https://doi.org/10.1189/jlb.1103581
Moldenhauer, Anja ; Frank, Richard C. ; Pinilla-Ibarz, Javier ; Holland, Gudrun ; Boccuni, Piernicola ; Scheinberg, David A. ; Salama, Abdulgabar ; Seeger, Karl ; Moore, Malcolm A S ; Nimer, Stephen D. / Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. In: Journal of Leukocyte Biology. 2004 ; Vol. 76, No. 3. pp. 623-633.
@article{e3156484cb99438c8faed2a00e84b0bc,
title = "Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins",
abstract = "Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells (DC) to induce a leukemia-specific immune response. In this study, three leukemic cell lines were investigated: Kasumi-1 and SKNO-1 (two acute myeloid leukemia (AML) cell lines carrying the (8;21)-chromosomal translocation, resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one) and REH, an acute lymphoblastic leukemia cell line with the (12;21)-chromosomal translocation and expression of translocation ETS-Bke leukemia-AML1. These fusion proteins are implicated in the pathogenesis of the lenkende state by recruiting corepressors and histone deacetylases (HDAC), which interfere with normal cell differentiation. In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor α, granulocyte macrophage-colony stimulating factor, c-kit ligand, and soluble CD40 ligand; yet, addition of the HDAC inhibitor (Hdi) trichostatin A enhanced DC differentiation with retention of the fusion transcripts. These leukemic DC showed high-level CD83 and human leukocyte antigen (HLA)-DR expression and had a high allostimulatory potential. Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42{\%} in parental Kasumi-1 and 83{\%} in parental REH cells, respectively. This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins.",
keywords = "Leukemia, Translocation, Vaccination",
author = "Anja Moldenhauer and Frank, {Richard C.} and Javier Pinilla-Ibarz and Gudrun Holland and Piernicola Boccuni and Scheinberg, {David A.} and Abdulgabar Salama and Karl Seeger and Moore, {Malcolm A S} and Nimer, {Stephen D}",
year = "2004",
month = "9",
day = "1",
doi = "10.1189/jlb.1103581",
language = "English",
volume = "76",
pages = "623--633",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins

AU - Moldenhauer, Anja

AU - Frank, Richard C.

AU - Pinilla-Ibarz, Javier

AU - Holland, Gudrun

AU - Boccuni, Piernicola

AU - Scheinberg, David A.

AU - Salama, Abdulgabar

AU - Seeger, Karl

AU - Moore, Malcolm A S

AU - Nimer, Stephen D

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells (DC) to induce a leukemia-specific immune response. In this study, three leukemic cell lines were investigated: Kasumi-1 and SKNO-1 (two acute myeloid leukemia (AML) cell lines carrying the (8;21)-chromosomal translocation, resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one) and REH, an acute lymphoblastic leukemia cell line with the (12;21)-chromosomal translocation and expression of translocation ETS-Bke leukemia-AML1. These fusion proteins are implicated in the pathogenesis of the lenkende state by recruiting corepressors and histone deacetylases (HDAC), which interfere with normal cell differentiation. In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor α, granulocyte macrophage-colony stimulating factor, c-kit ligand, and soluble CD40 ligand; yet, addition of the HDAC inhibitor (Hdi) trichostatin A enhanced DC differentiation with retention of the fusion transcripts. These leukemic DC showed high-level CD83 and human leukocyte antigen (HLA)-DR expression and had a high allostimulatory potential. Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42% in parental Kasumi-1 and 83% in parental REH cells, respectively. This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins.

AB - Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells (DC) to induce a leukemia-specific immune response. In this study, three leukemic cell lines were investigated: Kasumi-1 and SKNO-1 (two acute myeloid leukemia (AML) cell lines carrying the (8;21)-chromosomal translocation, resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one) and REH, an acute lymphoblastic leukemia cell line with the (12;21)-chromosomal translocation and expression of translocation ETS-Bke leukemia-AML1. These fusion proteins are implicated in the pathogenesis of the lenkende state by recruiting corepressors and histone deacetylases (HDAC), which interfere with normal cell differentiation. In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor α, granulocyte macrophage-colony stimulating factor, c-kit ligand, and soluble CD40 ligand; yet, addition of the HDAC inhibitor (Hdi) trichostatin A enhanced DC differentiation with retention of the fusion transcripts. These leukemic DC showed high-level CD83 and human leukocyte antigen (HLA)-DR expression and had a high allostimulatory potential. Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42% in parental Kasumi-1 and 83% in parental REH cells, respectively. This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins.

KW - Leukemia

KW - Translocation

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=4344654119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344654119&partnerID=8YFLogxK

U2 - 10.1189/jlb.1103581

DO - 10.1189/jlb.1103581

M3 - Article

C2 - 15197237

AN - SCOPUS:4344654119

VL - 76

SP - 623

EP - 633

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 3

ER -